The global hypoventilation management market is poised for significant growth, with its value expected to surpass an impressive USD 7.1 billion in 2023 and reach USD 11.9 billion by 2033. This growth is expected to be driven by an increasing prevalence of obesity, sleep disorders, and innovations in hypoventilation diagnostic devices, which are helping to detect and manage these conditions at early stages.
Hypoventilation, a condition in which individuals do not breathe in sufficient amounts of air, often leads to severe complications, including sleep apnea and chronic obstructive pulmonary disease (COPD). The rising global popularity of high-calorie foods and sedentary lifestyles is contributing to a surge in obesity rates, which is, in turn, fueling the growth of hypoventilation-related disorders. Early diagnosis through advanced diagnostic devices is playing a crucial role in identifying the problem early and improving patient outcomes.
Among the most notable advancements is the evolution of Positive Airway Pressure (PAP) devices, which have seen significant improvements in terms of design, safety, and efficacy. These devices, including smaller, cost-effective models designed for home use, are expected to drive greater adoption, particularly among individuals managing hypoventilation disorders in the comfort of their homes.
Key players in the hypoventilation management market are taking significant steps to enhance treatment options, including the development of medical devices and web-based applications. Notably, in May 2019, Spire Health launched a study aimed at developing new digital biomarkers to predict exacerbations and potential hospitalizations in patients with severe COPD. Such innovations are expected to alleviate the global burden of hypoventilation and improve patient quality of life.
Awareness initiatives by organizations and growing collaborations between pharmaceutical companies and healthcare providers are also contributing to market growth. For example, Boehringer Ingelheim and Optimum Patient Care introduced the APEX COPD patient registry in May 2019, a collaborative effort to better understand hypoventilation disorders and optimize treatment strategies in primary care settings.
With an expanding pipeline of potential medications targeting COPD and other hypoventilation disorders, the future of hypoventilation treatment looks promising. These efforts are set to propel the market forward, ensuring improved treatment outcomes and enhanced patient management across the globe.
As the market continues to evolve, both innovations in technology and the increasing awareness of hypoventilation’s impact are expected to shape the future of this critical healthcare segment, driving further advancements and growth in the coming years.
Key Takeaways from the Market Study:
- North America is expected to dominate the industry while reaching a market share of around 41% by end of the forecast period.
- The market in South Asia is projected to reflect a CAGR of 5.5% during the projected timeline.
- By disease type, chronic obstructive pulmonary disease is anticipated to account for maximum market share of 55% during the forecast period.
- Hospitals are projected to account for 71% market share by end-user, by end of 2033.
“Adoption of positive airway pressure devices and other product launches will bolster hypoventilation treatment market in the forecast period”- comments an FMI Analyst
Surge in Market Demand: Explore Comprehensive Trends and Analysis in Our Full Report!
Competitive Landscape:
The global Hypoventilation management market is highly competitive a due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings
Some recent developments in this industry are:
- In June 2022, Verona Pharma, a pharmaceutical company announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, a type of hypoventilation disorder. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
- In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for USD 270 Mn. These products are indicated for the treatment of various types of hypoventilation disorders
- In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Key Segments Profiled in the Hypoventilation Management Market Industry:
By Disease Type:
- Chronic Obstructive Pulmonary Disease
- Obesity Hypoventilation Syndrome (OHS)
- Central Alveolar Hypoventilation
- Neuromuscular Disorders
By Treatment Type:
- Oxygen Therapy
- Non-Invasive Mechanical Ventilation
- Drug Therapy
By End User:
- Hospitals
- Specialty clinics
- Home care
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
𝖤𝗑𝗉𝗅𝗈𝗋𝖾 𝖥𝖬𝖨’𝗌 𝖱𝖾𝗅𝖺𝗍𝖾𝖽 𝖮𝗇𝗀𝗈𝗂𝗇𝗀 𝖢𝗈𝗏𝖾𝗋𝖺𝗀𝖾 𝗈𝗇 𝖧𝖾𝖺𝗅𝗍𝗁𝖼𝖺𝗋𝖾 𝖬𝖺𝗋𝗄𝖾𝗍 𝖨𝗇𝗌𝗂𝗀𝗁𝗍𝗌 𝖣𝗈𝗆𝖺𝗂𝗇:
Point-of-care Cholesterol Monitoring Device Industry
Airway Management Devices Industry
Hypoparathyroidism Treatment Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube